证券日报网讯睿智医药（300149）11月25日在互动平台回答投资者提问时表示，截至2025年11月20日， 公司股东户数为39753户。 ...

Core Insights - The article highlights a trend of decreasing shareholder accounts among 660 companies, indicating a concentration of shares, with some companies experiencing declines for over three consecutive periods [1][2] Group 1: Shareholder Account Trends - 78 companies have reported a continuous decrease in shareholder accounts for more than three periods, with the most significant decline being 10 periods for companies like Rundu Co. and Mingpai Jewelry [1] - Rundu Co. has seen its shareholder accounts drop to 21,450, a cumulative decrease of 38.45%, while Mingpai Jewelry's accounts have fallen to 28,500, with a cumulative decline of 30.49% [1] - Other companies with notable declines include Yihau New Materials and *ST Huike, among others [1] Group 2: Market Performance - Among the companies with decreasing shareholder accounts, 25 have seen their stock prices rise, while 52 have experienced declines, with notable gainers including Allianz Ruishi, Ximai Food, and Qidi Design, which rose by 30.90%, 29.31%, and 20.72% respectively [2] - 26 companies outperformed the Shanghai Composite Index during this period, representing 33.33% of the group, with the highest excess returns from Ximai Food and Allianz Ruishi [2] Group 3: Industry and Institutional Activity - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery, automotive, and basic chemicals, with 10, 8, and 5 companies respectively [2] - In terms of institutional interest, 12 companies with decreasing shareholder accounts were subject to institutional research in the past month, with frequent inquiries for companies like Boying Special Welding and Ruizhi Pharmaceutical [2]

Summary of Key Points Core Viewpoint - On November 25, a block trade of 1.59 million shares of Ruizhi Pharmaceutical was executed at a transaction price of 8.23 yuan, representing a discount of 20.48% compared to the market closing price of 10.35 yuan, with a total transaction value of 13.0857 million yuan, accounting for 16.79% of the total trading volume for the day [1]. Group 1: Transaction Details - The block trade involved 1.59 million shares of Ruizhi Pharmaceutical, with a transaction price of 8.23 yuan per share [2]. - The total transaction amount reached 13.0857 million yuan, which is approximately 1.30857 million [2]. - The trade accounted for 16.79% of the total trading volume on that day [1]. Group 2: Market Context - The transaction price of 8.23 yuan reflects a significant discount of 20.48% from the market closing price of 10.35 yuan [1]. - The buyer was from CITIC Securities, while the seller was from Huafu Securities [2].

Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Core Insights - The world's first drug manufacturing system suitable for ADC (Antibody-Drug Conjugates) and nucleotide monomer synthesis was officially launched in Shanghai [1] - This system, developed by Ruizhi Pharmaceutical in collaboration with East China Normal University, utilizes femtosecond laser technology to carve complex chemical factories on chips [1] - The system is expected to usher the pharmaceutical industry into a new era of continuous, miniaturized, and intelligent manufacturing [1] Cost and Efficiency - The new system significantly shortens the drug development cycle and reduces the cost of nucleotide monomer synthesis by over 40% [1] - It addresses issues related to expensive raw materials and long reaction times inherent in traditional processes [1] Future Implications - The future of drug production is anticipated to shift towards "on-demand intelligent manufacturing," moving away from reliance on centralized large factories [1] - Production may become decentralized, extending to hospitals, communities, and even households [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业机构共同投资的概述 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 9 月 3 日召开 第六届董事会第十一次会议，审议通过了《关于全资子公司与专业投资机构共同 投资的议案》。为借助专业投资机构的投资能力、资金优势及风险控制能力，赋 能创新药产业协同，公司全资子公司北海睿智创业投资有限公司（以下简称"北 海睿智"）与专业投资机构深圳市投控东海投资有限公司（以下简称"投控东海"、 "基金管理人"）及其他有限合伙人深圳市罗湖产业促进合伙企业（有限合伙） 拟共同出资设立深圳市罗湖东海睿智医药产业合伙企业（有限合伙）（以下简称 "合伙企业"或"基金"），全体合伙人认缴出资总额为人民币 20,000 万元， 其中北海睿智作为有限合伙人以自有资金出资人民币 5,800 万元，占认缴出资总 额 的 29% 。 具 体 内 容 详 见 公 司 于 2025 年 9 月 3 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的《关于全资子公司与专业投资机构共同投资的公 告》（公告编号：2 ...

Core Insights - The recent launch of the drug micro-manufacturing system by Ruizhi Pharmaceutical in collaboration with East China Normal University marks a significant advancement in the field of antibody-drug conjugates (ADCs) and nucleotide phosphoramidite monomer synthesis [1][2] - This intelligent micro-flow technology addresses the bottleneck of "pilot scale-up" in drug development, transforming traditional production methods into continuous, smart, and precise "desktop" manufacturing [1] - The ADC micro-manufacturing system integrates multiple steps of the coupling reaction into a single chip, allowing for millisecond-level monitoring and precise control of key quality attributes, significantly reducing batch-to-batch variability [1] Summary by Sections Technology and Innovation - The newly released ADC micro-manufacturing system can shorten the process development and optimization time from weeks to days [1] - Key technical challenges such as chip manufacturing, stability, and multiphase fluid control have been overcome, achieving a 100% localization rate for core components and reducing overall costs by over 50% compared to imported solutions [1] Company Strategy and Market Position - The drug micro-manufacturing system enhances the company's one-stop, platform-based service capability, marking a significant step towards achieving certainty in ADC and small nucleic acid drug development [2] - The system is expected to reduce ADC drug process development time by 70% and lower the cost of nucleotide monomer synthesis by over 40% [2] - Ruizhi Pharmaceutical currently provides comprehensive new drug lifecycle services to global pharmaceutical companies, biotech firms, and research institutions, having established strategic partnerships with over 150 leading biopharmaceutical research organizations and enterprises [2] Educational Collaboration - East China Normal University's School of Pharmacy, established in May 2023, focuses on developing cutting-edge technologies such as artificial intelligence pharmacy, drug manufacturing, digital drugs, and nucleic acid and cell drugs [2] - The school aims to become a leading base for drug science and a training ground for future pharmaceutical talent, addressing both international frontiers and national strategic needs [2]

Group 1: Medical Device Industry in Shanghai - Shanghai Pudong is focusing on micro-nano robots, brain-like intelligence, and new biological materials in the medical device sector [1] - The region has established a solid foundation for the medical device industry, with over 1,200 Class III medical device registrations, accounting for approximately 40% of Shanghai's total [1] - Five innovative medical device products have been launched this year, with several pioneering products showing potential to become major market players [1] Group 2: AI Application Development - Alibaba's Qianwen APP international version is set to launch soon, aiming to compete directly with ChatGPT in the AI to C market [2] - The app quickly rose to the fifth position in the Apple App Store's free applications chart shortly after its public testing began [2] Group 3: Chinese Stock Market Outlook - UBS forecasts a prosperous year for the Chinese stock market in 2026, driven by factors such as innovation and supportive policies for private enterprises [3] - The MSCI China Index target for the end of next year is set at 100, indicating a potential 14% increase from current levels [3] - The market is expected to be more driven by earnings performance, with a positive outlook on internet, hardware technology, and brokerage sectors [3] Group 4: Lithium Battery Industry Challenges - The lithium battery industry is facing severe "involution" challenges, particularly in the lithium iron phosphate materials sector, which is experiencing intense competition and profit pressure [4] - The China Chemical and Physical Power Industry Association is advocating for capacity warning mechanisms to guide the industry [4] Group 5: Pharmaceutical Manufacturing Innovation - The world's first drug manufacturing system for antibody-drug conjugates (ADC) and nucleotide monomer synthesis has been launched in Shanghai [5] - This system significantly reduces the development and optimization cycle from weeks to days, with over 95% of core components being domestically sourced and costs reduced by over 50% compared to similar imported solutions [5] Group 6: ETF Market Growth - The ETF market has seen a historic high in issuance, with 322 ETFs launched this year, an 80% increase from the previous year [6] - Total issuance volume reached 2,446.44 million units, a nearly 92% increase year-on-year, with equity funds being the primary driver [6] - Leading institutions dominate the ETF market, with E Fund, China Universal, and Huaxia Fund being the top issuers [6] Group 7: Financial Support for Automotive Consumption - Beijing is increasing financial support for automotive consumption, particularly for new energy vehicles, through various loan and credit initiatives [7] - The plan includes optimizing financial products for different purchasing scenarios, such as first-time buyers and trade-ins [7] Group 8: Technology Enterprise Development Goals - Beijing aims to incubate 3,000 technology-based enterprises and 600 specialized and innovative enterprises by 2027 [8] - The initiative focuses on transforming significant technological achievements to meet national strategic needs and stimulate economic growth [8] Group 9: Power Interconnection Projects - Five power interconnection projects have been approved, enhancing China's cross-regional power exchange capabilities with a total investment of 24.4 billion yuan [9] - These projects will add 15 million kilowatts of inter-provincial power transmission capacity upon completion [9] Group 10: Technology Innovation Projects in Chongqing - Chongqing has announced 48 technology innovation projects with funding up to 40 million yuan per project, focusing on modern manufacturing and technological innovation [10] - The projects span four categories and twelve key industrial sectors, aligning with the city's strategic development goals [10]

Core Insights - The release of the world's first intelligent manufacturing system for ADC (Antibody-Drug Conjugates) and nucleotide monomer drugs was announced by Ruizhi Pharmaceutical in collaboration with East China Normal University [1] - This innovative achievement is expected to drive the pharmaceutical industry towards continuous, miniaturized, and intelligent upgrades, reshaping the overall paradigm of drug research and production [1] - The development signifies China's achievement in achieving self-control in core biopharmaceutical process equipment, providing new momentum for the high-quality development of China's innovative drug industry [1]

Core Insights - Ruizhi Pharmaceutical reported that as of November 10, 2025, the number of shareholders is 40,581 [2] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder numbers [2]